Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.

J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.

Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies—yet gaps persist, and research funding uncertainty threatens future gains.

Texas Oncology’s virtual care navigation pilot supported 740 patients on oral oncolytics across 11 community sites, offering a scalable model for at-home care.

Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.

"AI will not replace oncologists; it will help interpret complex data and design more precise, adaptive, personalized cancer treatment," the authors write.

Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.